Additional file 12: Table S1. The incident cases, age-standardized incidence and temporal trends of gastric cancer in countries from 1990 to 2019. Table S2. Joinpoint regression analysis of gastric cancer incidence in countries from 1990 to 2019. Table S3. Joinpoint regression analysis of gastric cancer incidence of annual percentage change (APC) in territories from 1990 to 2019. Table S4. Joinpoint regression analysis of gastric cancer incidence of average annual percentage change (AAPC) in territories from 1990 to 2019.

Crude and adjusted odds ratios for self-reported falls and balance/walking difficulty in the past 12 months by demographic, health- and cancer-related factors in breast cancer.

List of variables, detailed definition, and coding.

This datasets were extracted from the SEER Oncotype DX Database. Data clearing process was presented as a supplementary figure of the manuscript. (File format : SPSS 20.0 data file)

Crude and adjusted odds ratios for self-reported falls and balance/walking difficulty in the past 12 months by demographic, health- and cancer-related factors in prostate cancer.

Crude and adjusted odds ratios for self-reported falls and balance/walking difficulty in the past 12 months by demographic, health- and cancer-related factors in lung cancer.

Background: This study was designed to validate the prognostic significance of the ratio of positive to examined lymph nodes (LNR) in patients with colorectal cancer.Methods: 218,314 patients from the SEER database and 1,811 patients from the three independent multicenter were included in this study. The patients were divided into 5 groups on a basis of previous published LNR: LNR0, patients with no metastatic lymph nodes; LNR1, patients with the LNR between 0.1 and 0.17; LNR2, patients with the LNR between 0.18 and 0.41; LNR3, patients with the LNR between 0.42 and 0.69; LNR4, patients with the LNR >0.7. The 5-year OS and CSS rate were estimated using Kaplan-Meier method and the survival difference was tested using log-rank test. Multivariate Cox analysis was used to further assess the influence of the LNR on patients' outcome.Results: The 5-year OS rate of patients within LNR0 to LNR4 group was 71.2, 55.8, 39.3, 22.6, and 14.6%, respectively (p < 0.001) in the SEER database. While the 5-year OS rate of those with LNR0 to LNR4 was 75.2, 66.1, 48.0, 34.0, and 17.7%, respectively (p < 0.001) in the international multicenter cohort. In the multivariate analysis, LNR was demonstrated to be a strong prognostic factor in patients with < 12 and ≥12 metastatic lymph nodes. Furthermore, the LNR had a similar impact on the patients' prognosis in colon cancer and rectal cancer.Conclusion: The LNR allowed better prognostic stratification than the positive node (pN) in patients with colorectal cancer and the cut-off values were well validated.

The global household smart air conditioner market is experiencing robust growth, driven by increasing consumer demand for energy-efficient and technologically advanced cooling solutions. Rising disposable incomes, particularly in developing economies, coupled with escalating urbanization and a growing awareness of smart home technology are key factors fueling this expansion. The market is segmented by type (e.g., split, window, portable), technology (Wi-Fi, app-controlled, voice-activated), and energy efficiency ratings (SEER, EER). Major players like Carrier, Daikin, LG, and others are aggressively investing in R&D to enhance features such as improved energy efficiency, air quality monitoring (e.g., PM2.5 sensors), and advanced connectivity options like integration with smart home ecosystems. This competition is driving innovation and pushing down prices, making smart air conditioners accessible to a wider consumer base. We estimate the market size in 2025 to be approximately $15 billion, with a Compound Annual Growth Rate (CAGR) of around 12% from 2025 to 2033. This growth is projected to continue, although potential restraints include supply chain disruptions, fluctuations in raw material prices, and the increasing cost of advanced technology integration. However, despite these potential challenges, the long-term outlook remains positive. The integration of smart features with energy-saving capabilities is a significant selling point for consumers, encouraging a shift away from traditional air conditioning units. Furthermore, government initiatives promoting energy efficiency and sustainable technologies are creating a favourable regulatory environment for the market's expansion. Geographical variations exist; regions like North America and Europe currently hold significant market share due to high adoption rates and established infrastructure. However, rapid growth is expected in Asia-Pacific and other emerging markets due to increasing demand and rising middle-class populations. Continued innovation, strategic partnerships, and focused marketing efforts will be crucial for manufacturers to capture a larger share of this dynamic and expanding market.

Gay

## Overview

Gay is a dataset for object detection tasks - it contains Gingivitis annotations for 400 images.

## Getting Started

You can download this dataset for use within your own projects, or fork it into a workspace on Roboflow to create your own model.

  ## License

  This dataset is available under the [CC BY 4.0 license](https://creativecommons.org/licenses/CC BY 4.0).

Background and AimsThe NCCN guidelines recommended an assessment of ≥ 12 lymph nodes (LN) as an adequate LN dissection (LND) for rectal cancer (RC). However, the impact of adequate LND on survival in stage I RC patients remained unclear. Thus, we aimed to compare the survival between stage I RC patients with adequate and inadequate LND.MethodsA total of 1,778 stage I RC patients in the SEER database from 2010 to 2017 treated with radical proctectomy were identified. The association between ≥ 12 LND and survival was examined using the multivariate Cox regression and the multivariate competing risk model referenced to < 12 LND.ResultsStage I RC patients with ≥ 12 LND experienced a significantly lower hazard of cancer-specific death compared with those with < 12 LND in both multivariate Cox regression model (adjusted HR [hazard ratio], 0.44, 95% CI, 0.29-0.66; P < 0.001) and the multivariate competing risk model (adjusted subdistribution HR [SHR], 0.45, 95% CI, 0.30-0.69; P < 0.001). Further, subgroup analyses performed by pT stage. No positive association between ≥ 12 LND and survival was found in pT1N0 RC patients (adjusted HR: 0.62, 95%CI, 0.32-1.19; P = 0.149; adjusted SHR: 0.63, 95%CI, 0.33-1.20; P = 0.158), whereas a positive association between ≥ 12 LND and survival was found in pT2N0 RC patients (adjusted HR: 0.35, 95%CI, 0.21-0.58; P < 0.001; adjusted SHR: 0.36, 95%CI, 0.21-0.62; P < 0.001).ConclusionsThe long-term survival benefit of adequate LND was not found in pT1N0 but in pT2N0 RC patients, which suggested that pT2N0 RC patients should be treated with adequate LND and those with inadequate LND might need additional therapy.

Characteristics colon cancer patients, by receipt of same versus different hospital primary care and surgical care.

Demographic characteristics of patients in PHIS-assembled cohort compared to the National Cancer Institute’s SEER program.

Supplementary material 12.

12, 36-, and 60-month cancer-specific and overall survival rates in prostate cancer patients with bone metastasis, 17 SEER registries, 2010–2021.

Univariate and multivariate analysis of prognostic factors for 758 DCC patients.

ObjectivePulmonary enteric adenocarcinoma (PEAC) is a rare subtype of pulmonary adenocarcinoma that lacks effective treatment. The purpose of this research was to investigate the clinical characteristics, treatment, and prognosis of PEAC, as well as the impact of relevant factors on survival, thus providing a reference for the clinical management of patients with this disease.MethodsFor this study, we gathered clinical data from 26 patients with PEAC in the Affiliated Cancer Hospital of Zhengzhou University from June 2014 to June 2021. We used SEER*Stat software V8.3.5 to download the PEAC patients from the Surveillance, Epidemiology, and End Results (SEER) database. In total, 20 patients were identified. Clinical data, including general information, imaging findings, and treatment protocols, were obtained, together with a follow-up of disease regression. The relevant clinical data were then analyzed.ResultsIt included 12 males and 14 females out of 26 patients from China, whose mean age was (62.73 ± 11.89) years; 20 were in the lower lung, 11 were stage I-II, and 15 were stage III-IV. Five had EGFR mutations, and four had KRAS mutations. In terms of treatment, patients with stage I-II were primarily treated by surgery, and patients with stage III-IV were treated mostly by chemotherapy. We extended the follow-up date to January 2022. On completion of the follow-up visit, 11 patients died, and the remaining 15 patients survived. The overall survival (OS) of 26 patients was 2.0-76.0 months, while the mean was 53.1 months, and the median OS (mOS) was 38.0 months (95% CI:1.727-74.273). In the case of progression-free survival (PFS) times, it was 2.0-76.0 months, with a mean PFS of 31.0 months and a median PFS (mPFS) of 8.0 months (95% CI:4.333-11.667). The PFS of the 15 patients in stage III-IV was 2.0-17 months, while the mean PFS was 6.5 months and the mPFS was 6.0 months (95% CI:4.512-7.488). Out of the 20 patients identified in the SEER database, the average age was 69.9 years, with 14 males and 6 females. Of these patients, 8 were diagnosed with stage I-II, while the remaining 11 were diagnosed with stage III-IV. 10 underwent surgery, 4 received radiation therapy, and 9 received chemotherapy. The mean OS of the 20 patients was 67.5 months, mOS was 28.0 months (95% CI: 9.664- 46.336). For patients diagnosed with stage III-IV, the mean OS was 14.8 months and mOS was 20 months (95% CI: 4.713-35.287).ConclusionPEAC is rare, and the prognosis is determined mainly by the stage; patients who undergo surgery in stage I-II have a better prognosis.

Additional file 12: Original data of inner testing set of SEER.